SYDNEY, Nov 16 (Reuters) - Australia will spend A$1 billion
($726.3 million) underwriting construction of a vaccine
manufacturing plant under a deal with a unit of biomedical giant
CSL Ltd, guaranteeing supply of flu shots and
antivenins, the federal government said on Monday.
Under the deal, CSL vaccine subsidiary Seqirus would spend
A$800 million building the facility in the city of Melbourne,
while the government would guarantee purchase of its vaccines
for 10 years, local media reported.
The purchase agreement would begin when the new plant opens
in 2026, in time for the expiry of a current supply agreement
with CSL which runs until about 2025, media added.
"We're currently well placed, but we want to be even better
placed because who knows what will come," Health Minister Greg
Hunt told the Australian Broadcasting Corp.
"We'll have that national vaccine manufacturing capability
as well as the long-term contracts for flu and for anti-venoms."
Hunt added the new CSL plant would be the largest vaccine
manufacturing plant in the southern hemisphere.
The Australian government has already struck agreements with
CSL to supply two potential vaccines for the new coronavirus
which are being trialled by Britain's AstraZeneca Plc
and Australia's University of Queensland.
($1 = 1.3768 Australian dollars)
(Reporting by Byron Kaye)